[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
2. Xiao Y, Li JD, Shi HL, Liu JH, Feng YL, Li MD: [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer]. Ai Zheng; 2007 Apr;26(4):386-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
  • BACKGROUND & OBJECTIVE: In recent years, the neoadjuvant chemotherapy for cervical cancer has evoked more and more attention and has been used widely.
  • This study was to investigate the chemosensitivity of cervical cancer cells to antitumor drugs using in vitro MTT assay chemosensitivity test.
  • METHODS: The sensitivity of fresh human cervical cancer cells from 32 patients to 9 cytotoxic drugs was tested using in vitro MTT assay.
  • RESULTS: The cytotoxic activities of the 9 drugs for cervical cancer were in sequence from high to low as follows: liposomal paclitaxel, taxol, carboplatin (CBP), ifosfamide (IFO), etoposide (VP-16), 5-fluorouracil (5-FU), cisplatin (DDP), bleomycin (BLM), and cyclophosphamide (CTX).
  • Generally, cervical cancer cells were more sensitive to paclitaxel, taxol, and CBP than to other drugs (P<0.05) with inhibition rates of 56.56%, 55.66%, and 46.81%, respectively.
  • Stage Ib1 cervical cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 58.71%, 53.00%, and 49.25%, respectively; stage Ib2 cervical cancer cells were more sensitive to paclitaxel and taxol than to other drugs with inhibition rates of 65.26% and 50.06%.
  • Both moderately and poorly differentiated squamous cell cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 52.01%, 49.21%, and 40.02% for the former, and 60.02%, 61.16%, and 48.75% for the latter.
  • CONCLUSIONS: MTT assay, a sensitive and widely used chemosensitivity testing method, is helpful in sensitive drug screening and neoadjuvant chemotherapy regimen selection for cervical cancer.
  • Cervical cancer cells are more sensitive to paclitaxel, taxol, and CBP than to other tested drugs in this study.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / pathology. Cell Survival / drug effects. Uterine Cervical Neoplasms / pathology


6. Tangsiriwatthana T, Chumworathayi B, Yuenyao P, Luanratanakorn S, Pattamadilok J: Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer. Radiat Med; 2007 Dec;25(10):502-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer.
  • PURPOSE: The aim of this study was to determine responses, acute adverse effects, and survival outcomes of women with stage IB2 to IVA treated with weekly cisplatin concurrent with pelvic irradiation at Srinagarind Hospital.
  • MATERIALS AND METHODS: The medical records of 100 women with cervical cancer stage IB2 to IVA who were treated with weekly cisplatin 40 mg/m(2) concurrent with pelvic radiotherapy at Srinagarind Hospital between January 2003 and June 2006 were reviewed and analyzed.
  • Distribution according to International Federation of Gynecology and Obstetrics (FIGO) staging was IB2 1.0%, IIB 47.0%, IIIB 51.0%, and IVA 1.0%, respectively.
  • CONCLUSION: Weekly cisplatin (40 mg/m(2)) concurrent with pelvic irradiation for locally advanced cervical cancer was effective with acceptable toxicity in Thai women.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy






Advertisement